Anthropic buys a biotech startup for $400 million, and it has fewer than 10 employees

Anthropic has acquired Coefficient Bio, a stealth biotech-AI startup that was just over eight months old when the deal closed. The purchase cost more than $400 million and was paid entirely in Anthropic stock, with no cash component. For a company that has itself raised billions from Amazon, Google and other investors to build safe AI, it is an unusual move: using its own shares as currency to absorb another team, even a tiny one.

Coefficient Bio operated in stealth mode, with virtually no public presence and no disclosure about what it was building. The team has fewer than ten people, and almost all of them are former computational biology researchers from Genentech, one of the world's largest biopharmaceutical companies. That fact largely explains the price: Anthropic was not buying a finished product or a specific technology, but a rare, hard-to-replicate cluster of expertise at the intersection of deep learning and molecular biology. On the open market, such specialists number in the handful.

The acquired team will join Anthropic's healthcare and life sciences unit. That unit has existed inside the company for some time, but little is publicly known about it. Anthropic has traditionally preferred to move cautiously in medical areas, and not without reason: the cost of an error in biomedicine is incomparably higher than in consumer AI applications.

The context matters. Computational biology is one of the fields where AI is already rewriting the rules. A few years ago, DeepMind's AlphaFold showed that neural networks can predict the three-dimensional structures of proteins more accurately and faster than decades of traditional experimental research. The race has not slowed since: large language models are being applied to drug discovery, genomic data analysis, disease diagnosis and the prediction of molecular interactions. Anthropic, which has some of the most powerful foundation models in the industry, has evidently decided that the time has come for a serious push into biomedicine.

$400 million for eight months of work and a team of fewer than ten people is not just a market anomaly. It is a clear sign that specialists who can combine real AI expertise with a deep understanding of biological systems have become one of the scarcest resources in the tech industry. The Genentech alumni are not theorists: they worked on real drugs that went through clinical trials in living patients. They understand the regulatory environment, know the limits of experimental data, and know from experience how results that look beautiful on paper fall apart against the complexity of the real world. That applied intuition is what is being valued at hundreds of millions.

The structure of the deal is telling in itself. Payment exclusively in stock means the Coefficient Bio team is making a long-term bet on the growth and value of Anthropic, while the company does not spend its cash reserves on the acquisition. For a company that has already raised several billion dollars from major investors but is still operationally unprofitable, it is a rational way to add talent without burning liquidity.

Taken together, this points to a clear trend: leading AI labs are no longer limiting themselves to general-purpose models. They are methodically building vertical stacks, from the foundation model to deep specialized expertise in a specific industry. Medicine and biology have become the next key frontier. The Coefficient Bio acquisition is one of the first clear public signals that Anthropic intends to take part in this race in earnest.